Sargramostim in Treating Patients With Kidney Cancer That Has Spread to the Lung
Study Information
Alliance Study ID: NCCTG-N9953
NCT Study ID (ClinicalTrials.gov): NCT00006483
Disease or Cancer Type: Genitourinary Cancers – Kidney / Bladder / Urothelial / Testicular
Alliance Study Chair: Svetomir Markovic, MD, PhD
Status: COMPLETED
Study Description
RATIONALE: Colony-stimulating factors such as sargramostim may increase the number of immune cells found in bone marrow or peripheral blood and may be an effective treatment for patients with kidney cancer that has spread to the lung.
PURPOSE: Phase II trial to study the effectiveness of sargramostim in treating patients who have kidney cancer that has spread to the lung.
Related Publications
For publications related to this and other clinical trials, visit the Alliance Publications Application.
Data Sources & Contacts
Full trial details
For more Information